{"id":"motretinide","rwe":[{"pmid":"11586072","year":"2001","title":"Retinoids--which dermatological indications will benefit in the near future?","finding":"","journal":"Skin pharmacology and applied skin physiology","studyType":"Clinical Study"},{"pmid":"2407574","year":"1990","title":"The relevance of the mouse papilloma test as a predictor of retinoid activity in human psoriasis.","finding":"","journal":"Dermatologica","studyType":"Clinical Study"},{"pmid":"2980988","year":"1988","title":"Transplacental pharmacokinetics of teratogenic doses of etretinate and other aromatic retinoids in mice.","finding":"","journal":"Reproductive toxicology (Elmsford, N.Y.)","studyType":"Clinical Study"},{"pmid":"2444191","year":"1987","title":"Limb bud cell cultures for estimating the teratogenic potential of compounds. Validation of the test system with retinoids.","finding":"","journal":"Archives of toxicology","studyType":"Clinical Study"},{"pmid":"3319725","year":"1987","title":"New indications and new retinoids.","finding":"","journal":"Dermatologica","studyType":"Clinical Study"}],"tags":[{"label":"motretinide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D10AD05","category":"atc"},{"label":"Active","category":"status"},{"label":"Acne vulgaris","category":"indication"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"tasmadem","offLabel":[],"synonyms":["motretinide","tasmadem","tasmaderm","molrelinid"],"timeline":[],"approvals":[],"brandName":"Tasmadem","ecosystem":[{"indication":"Acne vulgaris","otherDrugs":[{"name":"adapalene","slug":"adapalene","company":"Galderma Labs Lp"},{"name":"ammonia","slug":"ammonia","company":""},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"},{"name":"azelaic acid","slug":"azelaic-acid","company":"Allergan"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"motretinide","explanation":"Think of sebum like the oil in your car. When your skin produces too much sebum, it can clog pores and lead to acne. Tasmadem helps reduce sebum production, making it harder for acne to form.","oneSentence":"Tasmadem works by inhibiting the production of sebum, a key factor in the development of acne.","technicalDetail":"Tasmadem is a retinoid, a class of compounds derived from vitamin A, which play a crucial role in regulating cell growth and differentiation. By inhibiting the activity of retinoic acid receptors, Tasmadem reduces the expression of genes involved in sebum production, ultimately leading to decreased sebum secretion and improved acne symptoms."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1849","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MOTRETINIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:51:11.060337","biosimilars":[],"competitors":[{"drugName":"tretinoin","drugSlug":"tretinoin","fdaApproval":"1971-10-20","patentExpiry":"Aug 22, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"retinol","drugSlug":"retinol","fdaApproval":"1953-02-20","relationship":"same-class"},{"drugName":"adapalene","drugSlug":"adapalene","fdaApproval":"1996-05-31","patentExpiry":"Sep 15, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"isotretinoin","drugSlug":"isotretinoin","fdaApproval":"1982-05-07","patentExpiry":"May 29, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"trifarotene","drugSlug":"trifarotene","fdaApproval":"2019-10-04","patentExpiry":"May 30, 2033","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"motretinide","indications":{"approved":[{"name":"Acne vulgaris","source":"DrugCentral","snomedId":88616000,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"tretinoin","brandName":"tretinoin","genericName":"tretinoin","approvalYear":"1971","relationship":"same-class"},{"drugId":"retinol","brandName":"retinol","genericName":"retinol","approvalYear":"1953","relationship":"same-class"},{"drugId":"adapalene","brandName":"adapalene","genericName":"adapalene","approvalYear":"1996","relationship":"same-class"},{"drugId":"isotretinoin","brandName":"isotretinoin","genericName":"isotretinoin","approvalYear":"1982","relationship":"same-class"},{"drugId":"trifarotene","brandName":"trifarotene","genericName":"trifarotene","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"W786807KL1","CHEBI":"CHEBI:135490","INN_ID":"4233","UMLSCUI":"C0129022","ChEMBL_ID":"CHEMBL519260","KEGG_DRUG":"D05082","DRUGBANK_ID":"DB13368","PUBCHEM_CID":"6314185","MESH_SUPPLEMENTAL_RECORD_UI":"C010832"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":10,"therapeuticAreas":["Dermatology"],"atcClassification":{"source":"DrugCentral","atcCode":"D10AD05","allCodes":["D10AD05"]},"biosimilarFilings":[],"recentPublications":[{"date":"2001 Sep-Oct","pmid":"11586072","title":"Retinoids--which dermatological indications will benefit in the near future?","journal":"Skin pharmacology and applied skin physiology"},{"date":"1990","pmid":"2407574","title":"The relevance of the mouse papilloma test as a predictor of retinoid activity in human psoriasis.","journal":"Dermatologica"},{"date":"1988","pmid":"2980988","title":"Transplacental pharmacokinetics of teratogenic doses of etretinate and other aromatic retinoids in mice.","journal":"Reproductive toxicology (Elmsford, N.Y.)"},{"date":"1987 Aug","pmid":"2444191","title":"Limb bud cell cultures for estimating the teratogenic potential of compounds. Validation of the test system with retinoids.","journal":"Archives of toxicology"},{"date":"1987","pmid":"3319725","title":"New indications and new retinoids.","journal":"Dermatologica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tasmadem, also known as Motretinide, is a small molecule drug in the motretinide class. It is used to treat Acne vulgaris. The commercial status of Tasmadem is currently unknown, and it is not clear if it is patented or available as a generic. As a pharma professional, it is essential to consider the potential safety risks associated with Tasmadem, although specific details are not available. Further research is necessary to understand its pharmacokinetic properties and clinical use.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}